Literature DB >> 15574430

Interleukin-18 is a pro-hypertrophic cytokine that acts through a phosphatidylinositol 3-kinase-phosphoinositide-dependent kinase-1-Akt-GATA4 signaling pathway in cardiomyocytes.

Bysani Chandrasekar1, Srinivas Mummidi, William C Claycomb, Ruben Mestril, Mona Nemer.   

Abstract

In patients with congestive heart failure, high serum levels of the proinflammatory cytokine interleukin (IL)-18 were reported. A positive correlation was described between serum IL-18 levels and the disease severity. IL-18 has also been shown to induce atrial natriuretic factor (ANF) gene expression in adult cardiomyocytes. Because re-expression of the fetal gene ANF is mostly associated with hypertrophy, a hallmark of heart failure, we hypothesized that IL-18 induces cardiomyocyte hypertrophy. Treatment of the cardiomyocyte cell line HL-1 with IL-18 induced hypertrophy as characterized by increases in protein synthesis, phosphorylated p70 S6 kinase, and ribosomal S6 protein levels as well as cell surface area. Furthermore, IL-18 induced ANF gene transcription in a time-dependent manner as evidenced by increased ANF secretion and ANF promoter-driven reporter gene activity. Investigation into possible signal transduction pathways mediating IL-18 effects revealed that IL-18 activates phosphoinositide 3-kinase (PI3K), an effect that was blocked by wortmannin and LY-294002. IL-18 induced Akt phosphorylation and stimulated its activity, effects that were abolished by Akt inhibitor or knockdown. IL-18 stimulated GATA4 DNA binding activity and increased transcription of a reporter gene driven by multimerized GATA4-binding DNA elements. Pharmacological inhibition or knockdown studies revealed that IL-18 induced cardiomyocyte hypertrophy and ANF gene transcription via PI3K, PDK1, Akt, and GATA4. Most importantly, IL-18 induced ANF gene transcription and hypertrophy of neonatal rat ventricular myocytes via PI3K-, Akt-, and GATA4-dependent signaling. Together these data provide the first evidence that IL-18 induces cardiomyocyte hypertrophy via PI3K-dependent signaling, defines a mechanism of IL-18-mediated ANF gene transcription, and further supports a role for IL-18 in inflammatory heart diseases including heart failure.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15574430     DOI: 10.1074/jbc.M411787200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.

Authors:  Balachandar Venkatesan; Anthony J Valente; Sumanth D Prabhu; Prakashsrinivasan Shanmugam; Patrice Delafontaine; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2010-06-09       Impact factor: 5.000

2.  Store-operated calcium entry is present in HL-1 cardiomyocytes and contributes to resting calcium.

Authors:  Chad D Touchberry; Chris J Elmore; Tien M Nguyen; Jon J Andresen; Xiaoli Zhao; Matthew Orange; Noah Weisleder; Marco Brotto; William C Claycomb; Michael J Wacker
Journal:  Biochem Biophys Res Commun       Date:  2011-11-06       Impact factor: 3.575

3.  Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

Authors:  Gipsy Majumdar; Robert J Rooney; I Maria Johnson; Rajendra Raghow
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

4.  β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.

Authors:  David R Murray; Srinivas Mummidi; Anthony J Valente; Tadashi Yoshida; Naveen K Somanna; Patrice Delafontaine; Charles A Dinarello; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2011-10-08       Impact factor: 5.000

5.  Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload.

Authors:  James T Colston; William H Boylston; Marc D Feldman; Chris P Jenkinson; Sam D de la Rosa; Amanda Barton; Rodolfo J Trevino; Gregory L Freeman; Bysani Chandrasekar
Journal:  Biochem Biophys Res Commun       Date:  2007-01-16       Impact factor: 3.575

6.  Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis.

Authors:  Andrew E Schade; Jennifer J Powers; Marcin W Wlodarski; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

7.  Cytokines profile of reverse cardiac remodeling following transcatheter aortic valve replacement.

Authors:  Juyong Brian Kim; Yukari Kobayashi; Tatiana Kuznetsova; Kegan J Moneghetti; Daniel A Brenner; Ryan O'Malley; Catherine Dao; Joseph C Wu; Michael Fischbein; D Craig Miller; Alan C Yeung; David Liang; Francois Haddad; William F Fearon
Journal:  Int J Cardiol       Date:  2018-11-01       Impact factor: 4.164

8.  Resveratrol blocks interleukin-18-EMMPRIN cross-regulation and smooth muscle cell migration.

Authors:  Balachandar Venkatesan; Anthony J Valente; Venkatapuram Seenu Reddy; Deborah A Siwik; Bysani Chandrasekar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-26       Impact factor: 4.733

Review 9.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

Review 10.  Role of inflammation in the progression of heart failure.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Øie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.